Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds
Strategic Communication and Public Relations

Heidelberg - Toronto: Exchange Program for Clinician and Medical Scientists

The German Cancer Research Center (DKFZ) and Princess Margaret Cancer Centre (PM) are joining forces as world leading cancer research centers and are happy to announce the start of their International Clinician and Medical Scientist Fellowship Program.

The exchange program for Clinician and Medical Scientists has been established to promote world-class, transatlantic professional training and education in the area of translational cancer research for emerging leaders in patient-oriented cancer research.

In a competitive selection process, both institutions have recruited their first program fellows who will soon start working on joint tandem research projects between laboratories of the DKFZ in Heidelberg, Germany, and the Princess Margaret Cancer Centre in Toronto, Canada.

Robert Vanner

Princess Margaret Cancer Centre fellow, Dr. Robert Vanner began his Medical Oncology training in Toronto in July 2020 after completing his PhD research in the Department of Molecular Genetics and MD program at the University of Toronto. With the DKFZ-Princess Margaret Cancer Centre Clinician and Medical-Scientist Fellowship Robert will work on a joint project entitled "Clonal Hematopoiesis as a Determinant of Metastasis and Immunotherapy Response in Breast Cancer" under the co-supervision of Dr. John Dick at the Princess Margaret Cancer Centre and Dr. Andreas Trumpp at the DKFZ. The project will investigate how clonal hematopoiesis, a process whereby a mutant hematopoietic stem cell disproportionately contributes to blood production, impacts breast cancer response to treatment and progression to metastasis. The proposed work offers the opportunity to assess if clonal hematopoiesis impacts the tumour microenvironment in ways that could favour metastasis such as by favoring immune evasion, or impact response to immunotherapy. The intent is to better understand mechanisms promoting breast cancer metastasis and identify means to prevent this disease's deadly progression.

"The DKFZ-PM Clinician and Medical-Scientist Fellowship Training Program will connect two world-leading institutions to answer exciting, impactful questions about cancer biology. This will provide the ideal bridge between clinical training and establishing my own research group and medical practice as a clinician scientist in Medical Oncology."



Kira Kornienko

German Cancer Research Center Fellow, Dr. Kira Kornienko, who will join from the Charité in Berlin, is a medical doctor specializing in Urooncology. She will be hosted in the Division of Cancer Epigenomics at the DKFZ and collaborate with PM's Functional Epigenomics Research Group on a joint project called PRO-SPeCT (PROstate cancer heterogeneity deconvolution through Single cell Profiling of Chromatin accessibility and Transcriptomic output). Generating novel insights in the progression of aggressive Prostate Cancer is a goal of this highly translational project, which could pave the way for the development of novel approaches to prevent, diagnose, stage and treat Prostate Cancer. Project results could potentially be translated back to the clinics. For example within new studies and treatment options, which will hopefully lead to an improvement in clinical prostate cancer care in the future.

"My interest in research was already awakened during my medical studies and I have consequently expanded my research skills while working on a variety of topics. Building on my clinical experience from Urooncology, I want to further complement my precision oncology portfolio by working on a unique prostate cancer research project. I am sure that taking advantage of the expertise and support of two of the most famous cancer research centers will help me to make the most of my time as a program fellow and beyond."

Both institutions consider the joint exchange program to develop into a transatlantic platform for professional oncology research training of its Clinician and Medical Scientist Fellows. In addition, the program will further advance the excellent long-term interactions between the participating centers and therefore directly contributes to future inter-institutional research collaborations.

to top
powered by webEdition CMS